Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Trade Desk Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.45 (market cap $12.58B), while Trade Desk Inc trades at $12.02 (market cap $5.83B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 2.2× Trade Desk Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Trade Desk Inc for 72 Days on average.
| HALO | TTD | |
|---|---|---|
Market Cap | $12.58B | $5.83B |
Volume | 2,179,278 | 15,864,392 |
Sector | Health | Media |
52-Week High | $115.22 | $54.13 |
52-Week Low | $61.63 | $11.92 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $14.49B | $4.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
The Trade Desk (TTD) trades at $12.08, down 0.12% on the day and showing bearish technical signals with mixed earnings performance. The company maintains strong profitability with 76.9% gross margins and 15.4% ROE, though revenue growth has slowed to 3% in 2026 projections. Recent news highlights competitive pressures from Amazon and Alphabet, with the stock down significantly from its 2024 peak.
While TTD's valuation appears attractive with low P/E and P/S ratios, investors face headwinds from slowing growth and intense competition. The consensus price target of $14.72 suggests moderate upside potential, but near-term catalysts appear limited as the company navigates market share challenges and workforce reductions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
